Latest News

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

From pancreatic cancer breakthroughs to pivotal FDA votes, this week’s oncology news highlights progress, setbacks, and shifting regulatory momentum.

The FDA has authorized expanded access to the RAS inhibitor daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

The FDA has approved the first PROTAC in any indication, supported by phase 3 VERITAC-2 data.

S-HIFU achieved 71% ADT-free survival at 30 months in recurrent prostate cancer post-radiation, with better outcomes in patients with lower PSA and Gleason scores.

Phase 3 FLASH2 ends early after interim analysis shows synthetic hypericin photodynamic therapy fails to improve CTCL outcomes, prompting deeper data review and regulator talks.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

Explore the April 2026 FDA oncology roundup: full approval for brexu-cel in MCL, priority reviews for I-DXd and zanidatamab, and key lung cancer NDA news.

The FDA's Oncologic Drugs Advisory Committee voted in favor 7 to 1 that benefits of capivasertib outweighed risks.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed key considerations for biomarker testing in upper GI cancers.

The FDA's ODAC voted 6-3 against camizestrant for HR+/HER2– breast cancer, citing concerns over the SERENA-6 trial design and a lack of overall survival data.

Clinicians discuss using KEAP1/STK11 mutations to guide CTLA-4 therapy escalation in NSCLC, aiming to overcome PD-1 resistance and improve 5-year survival goals.

The oral gamma secretase inhibitor varegacestat improved progression-free survival and overall response rate vs placebo; full results to be presented at ASCO.

Real-world data show community oncology care links to longer survival in metastatic breast cancer and NSCLC, beating national benchmarks.

Dr Alexander Olawaiye discusses the impact of the FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

The BCMA-CD3 bispecific antibody outperformed daratumumab plus pomalidomide and dexamethasone in double-class exposed patients.

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows rapid deep molecular responses and tolerable safety.

The COMPANION-002 trial in biliary tract cancer allowed crossover to the tovecimig arm which likely confounded overall survival data.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

Study finds Gemini and GPT catch oncology chart errors, improving documentation accuracy and patient safety with clinician oversight.

The DNA ImmunoBody therapy improved efficacy when added to ipilimumab and nivolumab, with a registrational phase 3 trial expected to begin later this year.

FDA accepted the NDA for zipalertinib to treat previously treated metastatic NSCLC with EGFR exon 20 insertion mutations. Target action date: 2/27/27.

NCCN now recommends taletrectinib for ROS1+ NSCLC with brain metastases, citing high intracranial response rates in TKI-naive and pretreated patient cohorts.

The FDA has has granted a priority review to zanidatamab-based regimens for the first-line treatment of patients with gastroesophageal adenocarcinoma.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

During a live event, Caitlin Costello, MD, discussed the AQUILA trial and its potential impact on treatment for high-risk smoldering myeloma.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

Explore real-world extensive-stage SCLC care, with frontline chemoimmunotherapy, steep therapy attrition, NCCN updates, and evidence favoring 4 chemotherapy cycles.